The human chorionic gonadotropin (HCG) mimics the natural hormone produced during pregnancy and aids in various fertility and pregnancy related applications. HCG injections are commonly prescribed for women undergoing fertility treatments to induce ovulation and support early pregnancy. It helps in egg maturation and follicular development during in vitro fertilization and helps implantation and early placenta formation after embryo transfer. The global Human Chorionic Gonadotropin (HCG) Market is estimated to be valued at US$ 710.88 Mn in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing research and development activities for expanding HCG applications is one of the key trends driving the HCG market growth. Researchers are exploring the usage of HCG beyond fertility indications. Studies indicate that HCG could potentially treat osteoporosis,Cachexia, and muscle wasting disorders. It may also have anti-cancer properties. Some clinical trials are under way to evaluate the efficacy of HCG in conditions such as prostate and breast cancer. The success of ongoing research studies would expand the therapeutic scope of HCG and boost its adoption rates significantly over the forecast period.
Segment Analysis
The global human chorionic gonadotropin (HCG) market is dominated by the pharmaceutical segment. Being a major clinical application, HCG drugs are widely used for fertility treatment and in assisted reproductive technologies like in-vitro fertilization (IVF). The fertility segment accounts for over 60% of the overall market share. Emergence of low-cost generics have boosted the adoption of HCG drugs especially in developing regions for infertility treatment.
Key Takeaways
The global human chorionic gonadotropin (HCG) market is expected to witness high growth over the forecast period.
Regional analysis: North America currently accounts for the largest share of the global HCG market due to increase in healthcare expenditure and presence of advanced healthcare facilities in the region. Asia Pacific is expected to grow at the fastest pace during the forecast period driven by rise in infertility rates, surge in fertility tourism industry and growing medical tourism in countries like India and China.
Key players operating in the human chorionic gonadotropin (HCG) market are Merck & Co., Inc., Ferring B.V., Fresenius SE & Co.KGaA, Lupin, Sun Pharmaceutical Industries Ltd, Lee BioSolutions, Serum Institute of India Pvt. Ltd., Scripps Laboratories, Sanzyme Biologics Pvt. Ltd., VHB Medi Sciences Limited, Bharat Serums And Vaccines Limited (BSV), Zydus Lifesciences Ltd, Corona Remedies Pvt. Ltd. Merck & Co. and Ferring B.V. are the two top players dominating the HCG drug market globally.
No comments:
Post a Comment